1.Does the Benefit of Thrombectomy in Large Strokes Depend on Perfusion–Diffusion Mismatch? A Large Stroke Therapy Evaluation Trial Post Hoc Analysis
Adrien Ter SCHIPHORST ; Caroline ARQUIZAN ; Guillaume TURC ; Julien LABREUCHE ; Bertrand LAPERGUE ; David S. LIEBESKIND ; Hilde HENON ; Nasreddine NOURI ; Jean-François ALBUCHER ; Christophe COGNARD ; Gaultier MARNAT ; Igor SIBON ; Benjamin GORY ; Sébastien RICHARD ; Olivier NAGGARA ; Mariam ANNAN ; Grégoire BOULOUIS ; Eker F. OMER ; Tae-Hee CHO ; Federico Di MARIA ; Romain BOURCIER ; Benoit GUILLON ; Michael OBADIA ; Michel PIOTIN ; Anna FERRIER ; Emmanuel CHABERT ; Mònica MILLÁN ; Liesjet van DOKKUM ; Tudor G. JOVIN ; Emmanuelle Le BARS ; Vincent COSTALAT
Journal of Stroke 2026;28(1):115-125
Background:
and Purpose Whether perfusion-diffusion mismatch modifies treatment effect of mechanical thrombectomy (MT) for large strokes is poorly known. To address this question, we conducted a post hoc secondary analysis of the Large Stroke Therapy Evaluation (LASTE) randomized controlled trial (RCT).
Methods:
The LASTE RCT compared MT plus best medical treatment (BMT) to BMT alone in patients with large infarct (Alberta Stroke Program Early CT Score 0–5) in the 0–7-hour timewindow. This secondary analysis was restricted to patients with available baseline MR perfusionweighted imaging. We investigated the potential heterogeneity of MT treatment according to the presence of perfusion-diffusion mismatch, defined as a mismatch ratio ≥1.2, calculated as the time-to-maximum >6 seconds cerebral volume divided by ischemic core volume. The primary outcome was better functional outcome (favorable shift in the distribution of modified Rankin Scale [mRS] at 90 days, analyzed using generalized odds ratio [GenOR]).
Results:
A total of 102/324 patients were included, among whom 55 (54%) had a perfusiondiffusion mismatch. No significant treatment effect heterogeneity by diffusion-perfusion mismatch was observed for the primary outcome (GenOR for better functional outcome: 1.70 [95% confidence interval, CI, 0.95 to 3.05] and 1.04 [95% CI, 0.57 to 1.87] in patients with and without mismatch, respectively; ratio of GenORs: 1.63 [95% CI, 0.71 to 3.74]; P for heterogeneity=0.24) or for the secondary efficacy and safety outcomes.
Conclusions
Our study found no evidence of heterogeneity of treatment effect with respect to benefit or safety in patients with unrestricted infarct size at baseline treated with MT by presence of perfusion-diffusion mismatch. An individual participant-data meta-analysis of RCT is needed for definitive conclusions.
2.Bilateral optic neuropathy related to severe anemia in a patient with alcoholic cirrhosis: A case report and review of the literature.
Lisa HUMBERTJEAN-SELTON ; Jérôme SELTON ; Nolwenn RIOU-COMTE ; Jean Christophe LACOUR ; Gioia MIONE ; Sébastien RICHARD
Clinical and Molecular Hepatology 2018;24(4):417-423
Anemia appears frequently in patients with alcoholic liver disease (ALD) but has never been linked to bilateral nonarteritic anterior ischemic optic neuropathy (NAION). A 65-year-old woman with a medical history of alcoholic cirrhosis was admitted for bilateral NAION. On admission, she was found to have a low arterial pressure and severe normocytic anemia (48 g/L). The anemia was related to chronic bleeding due to antral gastritis along with other factors associated with ALD. The applied treatment consisted of urgent transfusion followed by high doses of proton-pump inhibitors, iron and vitamin supplementation, and support in lifestyle measures. Her hemoglobin levels remained stable after 2 years but the patient still suffered from visual loss. This case highlights the link between anemia and bilateral NAION in ALD patients. The optic nerve head is prone to infarction in this context due to the vascularization characteristics of ALD. Hemoglobin levels should be monitored in ALD patients to avoid the severe complication of NAION.
Aged
;
Alcoholics*
;
Anemia*
;
Arterial Pressure
;
Female
;
Gastritis
;
Hemorrhage
;
Humans
;
Infarction
;
Iron
;
Life Style
;
Liver Cirrhosis, Alcoholic*
;
Liver Diseases, Alcoholic
;
Optic Disk
;
Optic Nerve Diseases*
;
Optic Neuropathy, Ischemic
;
Vitamins
3.Serum IGFBP4 concentration decreased in dairy heifers towards day 18 of pregnancy.
Marie M MEYERHOLZ ; Kirsten MENSE ; Michael LIETZAU ; Ana KASSENS ; Matthias LINDEN ; Hendrike KNAACK ; Elisa WIRTHGEN ; Andreas HOEFLICH ; Mariam RALIOU ; Christophe RICHARD ; Olivier SANDRA ; Hans Joachim SCHUBERTH ; Martina HOEDEMAKER ; Marion SCHMICKE
Journal of Veterinary Science 2015;16(4):413-421
This study was conducted to determine if the main components of the somatotropic axis change during the early phase of pregnancy in the maternal blood system and whether differences exist on day 18 after pregnancy recognition by the maternal organism. Blood samples of pregnant heifers (Holstein Friesian; n = 10 after embryo transfer) were obtained on the day of ovulation (day 0), as well as on days 7, 14, 16 and 18 and during pregnant, non-pregnant and negative control cycles. The oncentrations of progesterone (P4), oestrogen, growth hormone (GH), insulin-like growth factor-1 and -2 (IGF1, -2) and IGF-binding protein-2, -3 and -4 (IGFBP2, -3, -4) were measured. The mRNA expressions of growth hormone receptor 1A, IGF1, IGF2, IGFBP2, IGFBP3 and IGFBP4 were detected using RT-qPCR in liver biopsy specimens (day 18). In all groups, total serum IGF1 decreased from day 0 to 16. Notably, IGFBP4 maternal blood concentrations were lower during pregnancy than during non-pregnant cycles and synchronized control cycles. It can be speculated that the lower IGFBP4 in maternal blood may result in an increase of free IGF1 for local action. Further studies regarding IGFBP4 concentration and healthy early pregnancy are warranted.
Axis
;
Biopsy
;
Embryonic Structures
;
Female
;
Growth Hormone
;
Liver
;
Ovulation
;
Pregnancy*
;
Progesterone
;
Receptors, Somatotropin
;
RNA, Messenger

Result Analysis
Print
Save
E-mail